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1. Introduction
Infective  Endocarditis  is  a  microbial  infection  characterised  by  the  presence  of  septic
vegetations on the surface of the endocardium (Moreillon and Que, 2004). Infection most
commonly occurs on the heart valves that has been damaged by congenital defects such as
previous disease or trauma (Durack, 1995). As a result these sites have the ability to gener‐
ate turbulent blood flow which in turn can cause damage to inner most lining of the blood
vessels, the endothelium, which causes surface damage leading to exposure of underlying
matrix protein (Ruggeri, 2009). Once exposed this highly thrombogenic surface leads to rapid
platelet deposition and the formation of a fibrin network. Circulating bacteria from a transient
bacteremia  in  turn  binds  to  this  sterile  platelet  fibrin  nidus  which  allows  a  secondary
accumulation  of  platelets  that  encase  the  bacteria  leading  to  stable  thrombus  formation
(Moreillon and Que, 2004).
Despite  improvements  in  medical  and  surgical  therapy,  invasive  staphylococcal  disease
causing  infective  endocarditis  is  still  associated  with  a  severe  prognosis  and  remains  a
significant  therapeutic  challenge.  Once  a  disease  primarily  affecting  younger  patients
presenting with rheumatic heart disease, modern times see a significant increase in newer ‘at
risk’  categories  including  patients  with  long  term  indwelling  central  venous  catheters,
patients undergoing haemodialysis and invasive intravascular procedures such as arthroplas‐
ty,  immunocompromized  patients  and  intraveneous  drug  abusers  (Thuny  et  al.,  2012).
Treatment of infective endocarditis usually requires a multidisciplinary approach involving
specialists  in  infectious  disease,  cardiologists  and  cardiac  surgeons.  Current  treatment
regimes consist of aggressive prolonged antibiotic therapy, frequently combined with surgery
(Prendergast and Tornos, 2010, Wilson et al., 2007). Prolonged antibiotic use is often less than
successful as 40% of patients relapse within 2 months of finishing clinically effective therapy.
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Furthermore, prolonged exposure to antibiotics leads to a greater risk of adding to the global
problem of  multiple antibiotic  resistant  strains of  bacteria.  Surgery is  a  costly and risky
alternative, however necessary in up to 47% of patients (Castillo et al., 2000, Murdoch et al.,
2009). In many cases surgery is not preferable due to risks associated with cardiac failure,
further spread of infection leading to persistent sepsis due to surgical removal of an infected
thrombus and/or life threatening embolisation (Jault et al., 1997, Heiro et al., 2000, Thuny et
al., 2012, Remadi et al., 2007).
2. The Staphylococcus
Staphylococcus aureus is a gram positive pathogen that continues to cause a significant number
of community-acquired and nosocomial infections. It is a normal commensal of the human
body and usually lives in harmony with its host without causing symptoms. Its primary habitat
is the anterior nares in 20% of the population and is transiently associated with the rest (Foster,
2009). The success of S. aureus as an opportunistic pathogen is due in part to its expression of
a wide array of microbial surface components recognising adhesive matrix molecules
(MSCRAMM’s) (Patti et al., 1994). Using these MSCRAMM’s S. aureus uses a multitude of
mechanisms to attach either directly or indirectly to host cells including platelets (O'Brien et
al., 2002, Kerrigan et al., 2008, Miajlovic et al., 2010, Fitzgerald et al., 2006, Pawar et al., 2004,
George et al., 2006). It is for this reason that S. aureus is now the most common and most virulent
etiologic pathogen in infective endocarditis.
3. Platelets play a critical role in thrombosis and haemostasis
Platelets are small anucleate cell fragments of the larger haematopoietic precursor cell, the
megakaryocyte (Thon and Italiano, 2010) and are crucial mediators of haemostasis. Platelets
have no control over gene expression as they do not possess a nucleus however they have got
limited capabilities in translational protein synthesis (Lindemann et al., 2001b). The primary
role of platelets in haemostasis is to police the integrity of the endothelium to prevent blood
loss (Nieswandt et al., 2009). Platelets circulate close to the endothelial cell surface at high shear
as individual entities that ordinarily do not interact with any other cell types. A transition from
this resting state to an activated state can be rapidly initiated if platelets are exposed to an
appropriate stimulus. Disruption of the endothelial cell lining due to trauma or injury to the
vascular endothelium platelets rapidly accumulate at the site of injury (Gawaz et al., 2005).
Recruitment is a highly controlled event that is initiated by the adhesive interaction between
the exposed extracellular matrix proteins in damaged endothelium and specific membrane
receptors on the platelet (Tabuchi and Kuebler, 2008). Collagen (Santoro and Zutter, 1995),
vonWillebrand factor (vWf) (Ruggeri, 1999), fibronectin (Savage et al., 1998, Kasirer-Friede et
al., 2007) and thrombospondin (Jurk et al., 2003) constitute the exposed matrix proteins at the
site of injury. Athough plasma proteins such as fibrinogen/fibrin and vitronectin are not
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synthesized by endothelial cells they can bind to exposed matrix proteins and increase
adhesiveness at the damaged site (Ruggeri et al., 2006, Ruggeri and Mendolicchio, 2007).
Platelets express a vast array of membrane receptors that play a critical role in recognition of
matrix proteins. The initial interaction of platelets with the injured vessel wall occurs between
GPIbα and immobilised vonWillebrand factor (Chesterman and Berndt, 1986). This interaction
initiates the tethering of circulating platelets to the vessel wall. Platelets typically ‘roll’ over
the vWf in the direction of flow driven by shear forces experienced by the vasculature (Ruggeri,
2009). A loss of interaction between GPIb and vWf on one side of the platelet leads to the
formation of another GPIb-vWf interaction on the other side of the platelet which gives rise to
a rolling phenomenon. This rolling mechanism is critical to slowing down the platelet long
enough for a second interaction that anchors the platelet to the damaged site. This firm
adhesion can be mediated by several membrane receptors, some of which will have become
activated as a result of platelet rolling and others who are expressed on the platelet surface as
a result platelet activation (Jackson et al., 2009). Once firmly adhered, the platelets rearrange
cytoskeletal components which results in filopodia and llamelipodia extension leading to
flattening or spreading of the platelet. Platelet spreading is critical following firm adhesion as
it firstly allows the platelet withstand the shear forces experienced in the vasculature and
secondly it increases the platelet surface area thus covering more of the damaged site.
Following attachment, platelets undergo a series of highly controlled intracellular signalling
events that lead to the release reaction where platelets release the contents of its stored
intracellular granules. Alpha granules contain proteins such as P-selectin which mediates
adhesion of platelets to monocytes, neutrophils and lymphocytes, resulting in the formation
of platelet leukocyte complexes (Diacovo et al., 1996a, Diacovo et al., 1996b, Larsen et al.,
1989). These granules also contain many chemotactic agents which lead to the recruitment of
various inflammatory cells; platelet derived growth factor (PDGF) and 12-hydroxyeicosate‐
traenoic acid (12-HETE) which recruit neutrophils (Herd and Page, 1994, Mannaioni et al.,
1997); platelet factor 4 and platelet derived histamine releasing factor (PDHRF) which recruit
eosinophils in airway disease (Brindley et al., 1983, Frigas and Gleich, 1986); PDGF and
transforming growth factor β (TGF-β) which recruit monocytes and macrophages and TGF-
β which recruits fibroblasts (Deuel et al., 1982, Tzeng et al., 1985, Wahl et al., 1987). Platelet
granules also contain several mediators of tissue damage such as oxygen free radicals and
hydrolytic enzymes. Dense granules release cationic proteins that initiate vascular permea‐
bility and mediators that enhance aggregate formation such as adenosine diphosphate (ADP)
and serotonin (5-HT) (Rendu and Brohard-Bohn, 2001). Bioactive amines are also secreted from
platelets following activation including Thromboxane A2 (TxA2) and platelet activating factor
(PAF) (McIntyre et al., 2003, Patrono et al., 2001).More recently it has been shown that platelet
granules contain many antimicrobial peptides such as beta-lysin, platelet microbial protein
(PMP), neutrophil activating peptide (NAP-2), released upon activation normal T-cell ex‐
pressed and secreted (RANTES) and fibrinopeptides A and B (Johnson and Donaldson, 1968,
Donaldson and Tew, 1977, Kameyoshi et al., 1992, Yeaman et al., 1997, Krijgsveld et al., 2000).
Once activation is complete the platelet forms a new surface for additional platelets to adhere,
predominantly through GPIIb/IIIa crosslinking adjacent platelets through a fibrinogen bridge,
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resulting in aggregate formation. The final step sees and effective plug at the site of injury
that is reinforced by the conversion of fibrinogen to fibrin through the coagulation cascade
(Ruggeri et al., 2006).
4. The growing role of platelets in infection and immunity
Platelets are poorly recognised for their role in infection and immunity even though just like
professional phagocytes (neutrophils, macrophages and dendritic cells) platelets are derived
from the same haematopoietic stem cell, undergo chemotaxis (Clemetson et al., 2000), phago‐
cytose foreign particles (Youssefian et al., 2002), and secrete a multitude of products including
inflammatory mediators (Kameyoshi et al., 1992), cytokines (Lindemann et al., 2001a, Antczak
et al., 2010) and antimicrobial peptides (Tang et al., 2002, Mercier et al., 2004), all while directing
and recruiting several members of the innate immune system to the infected area (Cox et al.,
2011, Semple and Freedman, 2010). In addition, toll like receptors (TLR) which are a family of
pattern recognition receptors expressed by several professional phagocytes recognise con‐
served molecular motifs expressed on different classes of infectious agent (Janeway and
Medzhitov, 2002, Armant and Fenton, 2002). To date at least 13 TLRs have been described in
various immune and nonimmune cells in both human and mice. Recently human platelet have
been shown to express TLR1,2,4,6,8 and 9, reinforcing their role as primitive immune cells in
host defence (Cognasse et al., 2005, Shiraki et al., 2004, Aslam et al., 2006, Zhang et al., 2009,
Garraud and Cognasse, 2010, Andonegui et al., 2005, Keane et al., 2010). More recent studies
have also demonstrated that TLRs are also responsible for lipopolysaccharide (LPS)-induced
thrombocytopenia (Andonegui et al., 2005, Aslam et al., 2006).
5. Mechanisms of interaction
Bacteria can interact with platelet in two ways, they can either support platelet adhesion or
they can induce platelet aggregation. Platelet adhesion to immobilised bacteria is a measure
of the strength of the interaction, whereas platelet aggregation induced by bacteria is a measure
of the quality of the interaction. In contrast to typical platelet aggregation induced by physio‐
logical agonists such as adenosine diphosphate (ADP), collagen or thrombin, bacteria induce
an all or nothing response. This means that the bacteria either induce a maximal aggregation
or they don’t induce platelet aggregation at all, there is no intermediate response. Another
unique feature of bacteria induced platelet aggregation is a distinct pause in time before
aggregation takes place. This is typically called the lag time. Increasing the concentration of
bacteria shortens the lag time but never eliminates it. The average lag time to platelet aggre‐
gation following addition of Staphylococci is between 5-12 minutes. This is in contrast to the
lag time observed upon the addition of typical platelet agonists ADP or thrombin which have
a lag time less than 10 seconds.
There are 3 main interactions between bacteria and platelets. In the first interaction bacteria
express proteins that can directly interact with a surface receptor on the platelet. In this case
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the bacterial protein express ligand mimetic domains that act as agonists on the platelet
receptor thus triggering an intracellular signal that culminates in platelet activation. In the
second interaction bacterial proteins bind a plasma protein that is a natural ligand for a platelet
receptor. For example, bacteria can bind antibody which in turn bridges the bacteria to the
antibody receptor (FcγRIIa) expressed on the platelet. Once engaged the receptor results in the
generation of an intracellular signal leading to platelet activation. Finally bacteria may have
the ability to secrete products or toxins that in turn activate platelets. Engagement of the
product or toxin with a platelet receptor results in activation. These different mechanisms of
interaction may help explain the lag time to platelet aggregation. For example, the lag time
could be representative of the time taken to trigger a response or bind a plasma protein. A
major challenge in studying platelet bacterial interactions is that most bacteria can interact
with platelets using multiple mechanisms. This makes it incredibly difficult to identify either
the platelet receptors or the bacterial proteins involved in triggering thrombus formation.
Moreover not only are the interactions species specific but strain specific as well.
6. Staphylococci interactions with platelets
6.1. Indirect interaction (Released products)
Staphylococcus aureus was one of the first bacteria isolated from patients with acute endocar‐
ditis. Despite improvements in medical and surgical therapy, invasive staphylococcal disease
causing infective endocarditis is still the most frequent etiologic microorganism found in
patients (Rasmussen et al., 2011). Studies investigating the mechanism through which S.
aureus contributes to endocarditis dates back as far as the early 1900’s. By the mid 1900’s
significant attention had been placed on the involvement of S. aureus alpha (α)-toxin in
contributing to IE. Alpha-toxin is produced by almost all strains of S. aureus. Typically α-toxin
disrupts the cell membrane by binding to the lipid bilayer of platelets, erythrocytes and some
leukocytes, forming an oligomeric structure that forms a water filled transmembrane pore. In
1964 Siegel and Cohen made two critical observations; first, addition of α-toxin led to the loss
of single platelets as evidenced by turbidimetric aggregometry and second that addition of
α-toxin to human platelets resulted in leakage of intracellular ions; NAD+, K+ and ATP but
interestingly not protein, suggesting that α-toxin was not lysing the platelets (Siegel and
Cohen, 1964). Further studies by Bernheimer and Schwartz confirmed these reports and
demonstrated by electron microscopy that following exposure to α-toxin platelets swelled but
did not show signs of lysis (Bernheimer, 1965). These early studies suggested that α-toxin may
have the ability to generate a signal upon binding to the platelet. Focusing on this Arvand and
colleagues demonstrated that α-toxin did indeed trigger a platelet signal upon binding and
most importantly one that leads to secretion of intracellular contents including procoagulant
mediators, platelet factor 4 and factor V. Secreted factor V in turn associates with the platelet
membrane leading to assembly of the prothrombinase complex (Arvand et al., 1990). This
explains the major pathway responsible for the procoagulatory effects of α-toxin. In contrast
to these early findings Bayer et al. demonstrated that α-toxin did cause platelet lysis and this
led to the release of platelet microbial proteins (PMP’s) which was bactericidal to S. aureus.
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Using an animal model of endocarditis the authors demonstrated that different strains of S.
aureus differed in the expression of functional versus mutant forms of α-toxin. Under these
conditions, the S. aureus strains producing either minimal or no α-toxin were less virulent in
vivo than wild-type strains (Bayer et al., 1997). Wild-type S. aureus strains or indeed an isogenic
strain engineered to over-express α-toxin were associated with increased release of PMP from
platelets. These results suggest that when S. aureus releases α-toxin, platelets release PMP’s
therefore leading to a protective role for the host by destroying S. aureus.
Lipoteichoic acid (LTA) is an essential component of the cell wall of S. aureus and plays a key
role in host-pathogen interactions (Morath et al., 2005). LTA is anchored to the cell wall via
diacylglycerol, however following bacteriolysis induced by cationic proteins from leukocytes
or antibiotic treatment with certain antibiotics, LTA is released from the cell wall (Lotz et al.,
2006). LTA is a very potent stimulator of cells expressing the pattern recognition receptor, toll
like receptor 2 (TLR2) (Kawai and Akira, 2010). Functional TLR2 is expressed on a number of
immune cells including platelets (Blair et al., 2009, Keane et al., 2010, Ward et al., 2005). Work
by Sheu et al, demonstrated that LTA from S. aureus inhibited platelet aggregation, calcium
mobilisation and cyclic AMP in human platelets (Sheu et al., 2000a, Sheu et al., 2000b). It
remains to be seen whether TLR2 is mediating this inhibition of platelet signalling.
6.2. Indirect interaction (Cell wall proteins)
There are numerous cell wall proteins expressed on the surface of S. aureus that have been
demonstrated to bind to platelets and trigger platelet activation. The majority of these cell wall
proteins have been found to bind plasma proteins and bridge to a platelet receptor. Staphy‐
lococcal protein A is a widely expressed protein found on greater than 90% of S. aureus strains.
In 1979, Hawiger et al., demonstrated that protein A is capable of binding to immunoglobulin
G (IgG) which in turn bridges to the platelet antibody receptor, FcγRIIa. This interaction results
in platelet signal generation, GPIIbIIIa dependent platelet aggregation and serotonin release
from the platelet dense granules. Interestingly purified protein A failed to cause measureable
platelet aggregation and release of serotonin was significantly reduced (Hawiger et al., 1979).
Recent studies have demonstrated that protein A can bind to the A1 domain of the major
plasma protein vonWillebrand factor with high affinity (low nM range) (O'Seaghdha et al.,
2006) which serves as a receptor for GPIbα expressed on platelets (Andrews et al., 2003). More
recent studies have investigated this interaction under fluid shear conditions and demonstrat‐
ed that preincubating platelet rich plasma with a vonWillebrand Factor antibody or indeed
blocking the platelet GPIbα receptor with an inhibitory monoclonal antibody partially
inhibited the platelet-S. aureus interaction. Furthermore using a strain of S. aureus that is
deficient in protein A expression reduced its interactions with platelets (Pawar et al.,
2004).These results suggest that protein A plays a role in triggering platelet activation.
More recent studies demonstrated that multiple cell wall proteins expressed on S. aureus are
capable of interacting with and triggering platelet aggregation (O'Brien et al., 2002). Among
the cell wall proteins identified, clumping factor A (ClfA) and clumping factor B (ClfB) are
possibly the most extensively studied. ClfA and ClfB has been shown to bind a number of
plasma proteins including fibrinogen, IgG and complement, which in turn bridge the bacteria
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to specific platelet receptors and trigger activation. Binding each plasma protein individually
is not sufficient to trigger platelet aggregation. To trigger full platelet activation ClfA or ClfB
must bind specific IgG along with either fibrinogen or complement, IgG being the key
molecule. There are at least two distinct sites on each ClfA or ClfB that allows IgG and
fibrinogen bind at the same time. Once this occurs, fibrinogen binds to platelet GPIIbIIIa, IgG
binds to platelet FcγRIIa and together induces receptor clustering leading to activation of
signal transduction pathways culminating in platelet aggregation (Loughman et al., 2005,
Miajlovic et al., 2007). Deletion of the fibrinogen binding domain on ClfA or ClfB led to the
discovery of another much slower platelet aggregation (8-20 minutes versus 2-4 minutes).
Loughman et al initially demonstrated that complement must assemble on the S. aureus surface
and then cross link to complement receptors expressed on platelets. Similar to before, IgG binds
to FcγRIIa, complement proteins binds to complement receptors on platelets and together
induces receptor clustering leading to activation of signal transduction pathways culminating
in platelet aggregation (Loughman et al., 2005). Much controversy surrounds the existence of
complement receptors on platelets however the most convincing evidence of a complement
receptor is that demonstrated by Nyugen et al., who demonstrated the expression of
gC1qR/p33 following platelet activation. This suggests that an initial interaction leads to
platelet activation which in turn triggers expression of gC1qR/p33 on the platelet surface.
Expression of this receptor post activation most likely serves to anchor the bacteria to the
platelet.
A critical part of S. aureus survival in the host is the wide array of cell wall proteins it expresses
at various growth phases of its cell cycle. For example, ClfA is weakly expressed during the
exponential phase and strongly expressed during the stationary phase. In contrast to this
fibronectin binding protein A (FnbpA) is strongly expressed during the exponential phase of
growth and weakly expressed during the stationary phase of growth. FnbpA also plays a key
role in inducing platelet aggregation. The mechanism through which FnbpA induces platelet
aggregation is more or less identical to the mechanism that ClfA uses to induce platelet
aggregation. Fnbp contain a specific immunoglobulin binding domain (A domain) and a
separate fibronectin binding domain (BCD). FnBPA possesses two different but related
mechanisms of engaging and activating platelets (Fitzgerald et al., 2006). In the first mecha‐
nism, fibrinogen can bind to the A domain which crosslinks to GPIIb/IIIa, and specific
immunoglobulin must crosslink to FcγRIIa to trigger platelet activation and aggregation
(Fitzgerald et al., 2006). In the second mechanism fibronectin can bind to S. aureus via the
FnBPA BCD domain (Meenan et al., 2007, Raibaud et al., 2005). The signal to trigger platelet
activation/aggregation is complete when specific immunoglobulin binds the A domain of
FnBPA and cross links to platelet FcγRIIa inducing receptor clustering.
As discussed in chapter 2 serine rich proteins expressed by viridans streptococci play a critical
role in inducing platelet aggregation. S. aureus also expresses a highly glycosylated serine rich
protein called SraP on its surface (Siboo et al., 2005). Strain of S. aureus deficient in expression
of SraP has been shown to have reduced virulence in a rabbit model of endocarditis. Regardless
of the fact that SraP shares significant similarities with a number of other serine rich glyco‐
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proteins found in the streptococci that have been found to bind to platelet GPIbα (Kerrigan et
al., 2007, Plummer et al., 2005), SraP does not appear to bind to this platelet receptor.
While all of these studies are critical to our understanding of the molecular mechanisms
involved in aggregate formation, one must be aware of the relevance of these findings to
physiological conditions experienced in the vasculature. For example, almost all of the studies
carried out to date have been carried out under non-physiological stirring or using static
adhesion assays, neither of which are representative of the conditions experienced in the
vasculature. Many reports in the literature in recent times have clearly demonstrated that the
local fluid environment in the circulation critically affects the molecular pathways of cell-cell
interactions (Varki, 1994). To address this several attempts have been made to create an
environment more representative of conditions experienced in the circulation. Rheology is a
useful technique that can be employed to shear cells at physiological rates. Using a cone and
plate viscometer, Pawar et al. demonstrated that when S. aureus is mixed with whole blood
isolated from a healthy individual thrombus formation could be observed. Additional studies
demonstrated that the thrombus formation was dependent on multiple S. aureus cell wall
proteins including protein A, ClfA, SdrC, SdrD, SdrE (Pawar et al., 2004). A potential limitation
to using a cone and plate viscometer is that is measures thrombus formation in a soluble setting
and it is well established that thrombus formation on a heart valve in IE occurs under stable
conditions. To address this Kerrigan et al. developed a parallel flow chamber to assess the
interaction between S. aureus and platelets in whole blood. To do this S. aureus was immobilised
on a glass slide (to mimic the focal infection on a heart valve) and whole blood was perfused
over the bacteria at both arterial and venous shear rates. This method demonstrated that
platelets perfused over immobilised S. aureus under arterial shear led to a very strong adhesion,
followed by rapid aggregate formation. Deletion of ClfA (but not protein A or FnbpA) from
S. aureus abolished adhesion and subsequent aggregate formation. Using a plasma-free system,
fibrinogen led to single platelet adhesion but not aggregate formation. Specific immunoglo‐
bulin failed to have any effect on either platelet adhesion or aggregation. However, addition
of fibrinogen and specific immunoglobulin together to the plasma-free system led to platelet
adhesion followed by aggregate formation thus highlighting the importance of fibrinogen and
IgG in aggregate formation. Interestingly platelets did not adhere to or induce aggregate
formation under low shear conditions using the parallel flow chamber (Kerrigan et al., 2008).
6.3. Direct interaction (Cell wall proteins)
A growing concern about studies to date is the apparent lack of contrast with conditions
experienced physiologically. In vivo, when S. aureus enters the blood stream it is in an envi‐
ronment where iron is sequestered in haem or haemoglobulin. The lack of iron available in
vivo inactivates the Fur repressor in S. aureus that results in an up-regulation of a number of
genes that typically wouldn’t be expressed in when growing in normal laboratory bacterial
growth media. A growing family of iron-regulated surface determinant proteins have been
recently identified as expressed in S. aureus grown in iron limited conditions. Using surface
plasmon resonance, Miajlovic et al. demonstrated that one family member, iron-regulated
surface determinant B (IsdB), can bind directly (in the absence of plasma proteins) to the
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purified platelet fibrinogen receptor GPIIb/IIIa. As a result of this binding subsequent studies
demonstrated the ability of the wildtype S. aureus strain to support platelet adhesion and
induce platelet aggregation. A. S. aureus strain defective in expression of IsdB displayed a
reduce ability to adhere to or induce platelet aggregation (Miajlovic et al., 2010).
7. Final thoughts and future directions
Infective endocarditis is notoriously difficult to treat as antibiotics are incapable of penetrating
the growing thrombus to reach the encased microorganisms. As a result of this the in-hospital
mortality rate can be as high as 36% (Botelho-Nevers et al., 2009). Even with treatment, 40% of
patients with infective endocarditis relapse within 2 months of finishing clinically effective
therapy (Netzer et al., 2002). Furthermore, approximately 25% of patients with infective
endocarditis eventually require surgery, usually within 2 years after completing therapy
(Olaison and Pettersson, 2003). These statistics reflect the poor delivery and penetration of
antibiotic into the growing thrombus. The costs associated with hospitalization (of which the
average stay in hospital is 30 days), surgery and prolonged antibiotic treatment is extremely
high placing a severe burden on already over-stretched healthcare systems though out the
world. The danger of S. aureus invasive disease is also compounded by the rapidly increasing
global widespread occurrence of multiple antibiotic resistant strains (MRSA and VRSA) which
is directly attributed to prolong use of antibiotics. The greater the duration of exposure of an
antibiotic to bacteria, the greater the risk of development of resistance and this is irrespective
of the severity of the need for antibiotics. If this is not addressed soon, acquired resistance may
produce a virtually untreatable pathogen. Therefore it is of the utmost importance that we
understand the molecular interactions that lead to the development of thrombus formation on
the heart valves. This will serve two purposes, first it may lead to the development of novel
therapies that will prevent the formation of a thrombus on the heart valve and secondly as a
result will overcome the problem associated with getting clinically effective concentrations of
antibiotic to the site of infection on the heart valve.
Potential drug targets identified from studies over the years suggest that blocking the inter‐
action between IgG and platelet FcγRIIa may indeed prevent platelet receptor clustering and
thus inhibit thrombus formation. Blockade of the platelet FcγRIIa receptor has distinct
advantages over other anti-platelet agents as inhibitors of FcγRIIa do not affect the platelet
response to other agonist and therefore does not compromise essential platelet functions.
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